CDC seems to play a predominant role in mediating rituximab-induced cell death in CLL [83] due to high leukocytosis and therefore high accessibility of tumor cells to complement complex, which is reflected by the rapid exhaustion of complement and C3b(i) deposition [84]. This evidence concerns the gene C3 and B-cell chronic lymphocytic leukemia.